As 2016 came to a close, so too did a significant number of business deals involving diagnostic companies, tests and testing systems. Here’s a summary of some of the recent transactions affecting diagnostics. MERGERS & ACQUISITIONS Acquiring Company Target Deal Summary Agilent Technologies Multiplicom, Belgiumbased molecular diagnostics firm spun off from Univ. of Antwerp in 2011 Price: €68 million ($70.6 million) in cash AT to offer jobs to all 90 M employees Lure is M’s BRCA Tumor MASTR Plus Dx test, first ovarian cancer companion test to get CE-IVD designation in Europe Menarini-Silicon Biosystems Janssen Diagnostics Price: Undisclosed MSB acquires JD’s Cellsearch circulating tumor cell system for monitoring breast, prostate and colorectal cancers Cellsearch is only breast cancer monitoring system approved by China FDA Abbott Laboratories St. Jude Medical $25 billion merger European Commission OKs on antitrust grounds provided that: i. SJ divests Angio-Seal and Femoseal vascular closure assets; and ii. A divests Vado steerable sheath All latter assets already slated for sale to Japanese firm Terumo for $1 billion Takara Bio USA Holdings Rubicon Genomics Price: $75 million Helps T fortify position in pre-analytical genetic sample preparation and expand into in vitro fertilization Grifols Hologic, Inc.’s blood screening assets […]